- Home
- CMPX vs TCRX Comparison
CMPX vs TCRX Comparison
Compare CMPX & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- TCRX
- Stock Information
- Founded
- CMPX 2014
- TCRX 2018
- Country
- CMPX United States
- TCRX United States
- Employees
- CMPX N/A
- TCRX N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- TCRX Health Care
- Exchange
- CMPX Nasdaq
- TCRX Nasdaq
- Market Cap
- CMPX 291.8M
- TCRX 82.1M
- IPO Year
- CMPX N/A
- TCRX 2021
- Fundamental
- Price
- CMPX $2.78
- TCRX $1.51
- Analyst Decision
- CMPX Strong Buy
- TCRX Strong Buy
- Analyst Count
- CMPX 9
- TCRX 6
- Target Price
- CMPX $12.67
- TCRX $9.50
- AVG Volume (30 Days)
- CMPX 930.5K
- TCRX 604.8K
- Earning Date
- CMPX 08-11-2025
- TCRX 08-11-2025
- Dividend Yield
- CMPX N/A
- TCRX N/A
- EPS Growth
- CMPX N/A
- TCRX N/A
- EPS
- CMPX N/A
- TCRX N/A
- Revenue
- CMPX $850,000.00
- TCRX $4,421,000.00
- Revenue This Year
- CMPX N/A
- TCRX $159.20
- Revenue Next Year
- CMPX N/A
- TCRX N/A
- P/E Ratio
- CMPX N/A
- TCRX N/A
- Revenue Growth
- CMPX N/A
- TCRX N/A
- 52 Week Low
- CMPX $0.77
- TCRX $1.02
- 52 Week High
- CMPX $4.08
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- CMPX 68.90
- TCRX 50.74
- Support Level
- CMPX $2.50
- TCRX $1.39
- Resistance Level
- CMPX $2.71
- TCRX $1.73
- Average True Range (ATR)
- CMPX 0.19
- TCRX 0.13
- MACD
- CMPX 0.01
- TCRX -0.01
- Stochastic Oscillator
- CMPX 87.14
- TCRX 38.24
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.